Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
170
Employees170
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
170
Employees170

STOK Key Statistics

Market cap
2.04B
Market cap2.04B
Price-Earnings ratio
-11.51
Price-Earnings ratio-11.51
Dividend yield
Dividend yield
Average volume
1.40M
Average volume1.40M
High today
$33.50
High today$33.50
Low today
$32.21
Low today$32.21
Open price
$32.63
Open price$32.63
Volume
357.93K
Volume357.93K
52 Week high
$40.22
52 Week high$40.22
52 Week low
$11.19
52 Week low$11.19

Stock Snapshot

The current Stoke Therapeutics(STOK) stock price is $32.71, with a market capitalization of 2.04B. The stock trades at a price-to-earnings (P/E) ratio of -11.51.

On 2026-07-01, Stoke Therapeutics(STOK) stock traded between a low of $32.21 and a high of $33.50. Shares are currently priced at $32.71, which is +1.6% above the low and -2.4% below the high.

Stoke Therapeutics(STOK) shares are trading with a volume of 357.93K, against a daily average of 1.4M.

In the last year, Stoke Therapeutics(STOK) shares hit a 52-week high of $40.22 and a 52-week low of $11.19.

In the last year, Stoke Therapeutics(STOK) shares hit a 52-week high of $40.22 and a 52-week low of $11.19.

STOK News

TipRanks 1d
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 1d
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study

Stoke Therapeutics (STOK) announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolli...

Simply Wall St 3d
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics? - simplywall.st

...

Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics? - simplywall.st

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.